GHRP-6: Complete Guide to Dosage, Side Effects, and How It Compares to Ipamorelin

What Is GHRP-6?

GHRP-6 (Growth Hormone Releasing Peptide 6) is a synthetic hexapeptide discovered in the late 1980s during early research into synthetic growth hormone secretagogues. It was among the first compounds to demonstrate that GH release could be triggered through the ghrelin receptor pathway, independent of GHRH. That discovery fundamentally changed how researchers thought about GH axis modulation and eventually led to the development of the entire GHRP family, including GHRP-2, hexarelin, and ultimately ipamorelin.

GHRP-6 remains in active use in research communities, though it has largely been displaced in research stacks by ipamorelin. The reason is straightforward: ipamorelin was engineered specifically to address GHRP-6's main drawbacks (cortisol elevation and pronounced hunger) while preserving comparable GH release. For researchers who specifically want those side effects, or who want maximum raw GH stimulus without prioritizing selectivity, GHRP-6 still has a defined place.

How GHRP-6 Works

GHRP-6 is a synthetic mimetic of ghrelin, the endogenous gut-produced hunger hormone that also acts as a GH secretagogue. When administered, it binds the ghrelin receptor (GHSR-1a) at multiple sites:

• Anterior pituitary: GHSR-1a agonism triggers calcium mobilization in somatotroph cells, driving GH exocytosis. This is the intended research effect.
• Hypothalamus: GHSR-1a activation in the arcuate nucleus drives NPY/AgRP neuron firing, which stimulates appetite and promotes energy intake. This is the source of the hunger side effect.
• Adrenal axis: GHRP-6 stimulates ACTH release from the pituitary alongside GH, which drives adrenal cortisol production. This is the cortisol side effect.

The GH released in response to GHRP-6 then stimulates hepatic IGF-1 production over the following hours. IGF-1 mediates the anabolic downstream effects: protein synthesis upregulation, satellite cell activation in skeletal muscle, collagen synthesis in connective tissue, and lipolysis in adipose tissue. These are the same IGF-1-mediated effects that drive interest in all GHRP compounds.

The key structural difference that separates GHRP-6 from ipamorelin is that GHRP-6's D-Trp at position 2 is retained from the original peptide design and does not discriminate between pituitary GH secretion and the hunger/cortisol pathways. Ipamorelin's modified structure achieves the pituitary selectivity that GHRP-6 lacks.

GHRP-6 Dosage Protocols

Standard dosing range

Research literature and community protocols converge on 100-300 mcg per injection, 2-3 times daily. The GH response is dose-dependent up to approximately 100-150 mcg, after which the pituitary response plateaus (ghrelin receptor saturation), while side effects continue to scale with dose. This is an important practical consideration: going from 100 mcg to 300 mcg does not triple the GH response but does substantially increase hunger and cortisol elevation.

Fasting requirement

Like all GHRPs, GHRP-6 should be injected in a fasted state. Insulin, elevated after carbohydrate or protein consumption, strongly suppresses pituitary somatotroph responsiveness. A minimum 2-3 hour fast before injection is standard, with food avoided for 30-45 minutes post-injection. This is especially important for morning and pre-sleep dosing. The conflict between GHRP-6's appetite stimulation (which drives food cravings) and the need for fasting around injections is one of the practical frustrations researchers note with this compound versus ipamorelin.

Timing rationale

The same timing logic that applies to all GHRPs applies to GHRP-6. Pre-sleep injection amplifies the largest endogenous GH pulse (which occurs in early slow-wave sleep). Morning fasted injection capitalizes on low insulin after the overnight fast. Pre-workout injection combines with exercise-driven GH release. The pre-sleep injection is generally considered highest priority if only one daily injection is used.

Reconstitution

GHRP-6 is supplied as lyophilized powder in vials of 5 mg. Reconstitute with bacteriostatic water. A 5 mg vial with 2.5 mL of BAC water yields 2,000 mcg/mL (2 mg/mL); a 100 mcg dose is 0.05 mL (5 units on an insulin syringe). A 200 mcg dose is 0.1 mL (10 units). Store reconstituted peptide refrigerated at 2-8°C and use within 28-30 days. See the reconstitution guide for full sterile technique.

GHRP-6 Side Effects

Hunger (the most noticeable effect)

The hunger response from GHRP-6 is distinctive and often described as intense. It typically begins within 20 minutes of injection, peaks around 30-45 minutes, and subsides over 1-2 hours. It is a direct pharmacological effect of GHSR-1a activation in the hypothalamus, not a secondary consequence of GH or IGF-1 changes. For researchers in a caloric surplus or bulking context, this appetite drive is sometimes considered a feature rather than a side effect. For researchers targeting fat loss or maintaining a caloric deficit, it creates a meaningful compliance challenge that ipamorelin largely avoids.

Cortisol elevation

Published research in humans documents ACTH and cortisol elevation following GHRP-6 injection, typically reaching 1.5-2x baseline within 30-60 minutes at 100 mcg doses. Cortisol returns toward baseline within 2-3 hours. The practical significance depends on protocol: a single pre-sleep injection produces one cortisol spike per day, which most researchers tolerate without concern. Three injections daily creates three spikes, and sustained elevated cortisol is catabolic to muscle tissue, immune-suppressive, and counterproductive to the anabolic goals of GH axis optimization. This is why ipamorelin, with its minimal cortisol elevation, is preferred for higher-frequency or longer-duration protocols.

Prolactin elevation

Moderate prolactin elevation has been documented with GHRP-6 use. At research doses, this is generally not clinically significant in males or females for short cycles. Extended high-dose use with significant prolactin elevation can theoretically contribute to gynecomastia in males or menstrual irregularity in females, though these outcomes are not commonly reported in the GHRP-6 literature at typical doses.

Water retention

Some water retention is common with all GHRP compounds due to GH and IGF-1 activity, which increases sodium and fluid retention. This is usually mild and resolves when the compound is discontinued. It is not specific to GHRP-6 but is worth noting for researchers monitoring body composition changes.

GHRP-6 vs GHRP-2 vs Ipamorelin

These three compounds occupy different positions in the GHRP family, distinguished primarily by selectivity and side effect profile rather than mechanism class (all three act on GHSR-1a).

GHRP-2 is the most potent of the three for raw GH release but also produces the most significant cortisol and prolactin elevation. GHRP-6 sits between GHRP-2 and ipamorelin on the potency-selectivity spectrum: somewhat higher GH stimulus than ipamorelin (though the gap narrows with combination stacking), meaningful cortisol tradeoff, and the distinctive strong hunger effect.

The practical question is whether the higher GH stimulus from GHRP-6 or GHRP-2 justifies the cortisol and hunger tradeoffs versus ipamorelin. For most research protocols, the answer is no, particularly because the GH advantage of GHRP-6 over ipamorelin narrows substantially when either is combined with CJC-1295. The combination drives GH response high in both cases, making the GHRP component selection more about side effect tolerance than stimulus magnitude.

GHRP-6 with CJC-1295: The Classic Stack

GHRP-6 and CJC-1295 were one of the earliest defined GHRH/GHRP research stacks and remain in documented use. The mechanism is complementary: CJC-1295 binds the GHRH receptor (GHRH-R) and extends the somatotroph preparation window, while GHRP-6 binds GHSR-1a and triggers the GH release pulse. Together, the GH response is substantially greater than either alone, following the same synergistic logic as the more commonly used CJC-1295 plus ipamorelin combination.

The practical consideration for the GHRP-6 version of this stack is that the GHRP-6 side effects (hunger, cortisol) remain present and scale with dose. Most researchers transitioning from GHRP-6 to ipamorelin as the GHRP component of a CJC-1295 stack report similar GH axis results with substantially fewer side effects. The GHRP-6 plus CJC-1295 stack is most relevant for researchers who specifically want the appetite-stimulating effect (for bulking or metabolic research contexts) or who have historical data from this combination they are replicating.

Standard combined dosing: 100-200 mcg CJC-1295 plus 100-200 mcg GHRP-6 per injection, 1-2 times daily. The two can be co-administered in the same syringe when reconstituted with compatible carriers.

When GHRP-6 Makes Sense Over Ipamorelin

Given ipamorelin's more favorable side effect profile, there are specific contexts where GHRP-6 is chosen deliberately:

Cycle Length and Off Periods

GHRP-6 shows moderate receptor desensitization with extended use, more than ipamorelin but less than hexarelin. Common patterns:

• 6-8 weeks on, 4 weeks off: The most frequently cited structure for 2-3 injections daily. The off period allows GHSR-1a receptor density to recover and prevents accumulated cortisol effects.
• 8-10 weeks on, 4 weeks off: Sometimes used at lower doses (100 mcg twice daily) where desensitization concern is lower.
• Alternating with ipamorelin: Some researchers cycle between GHRP-6 (for bulking or acute phases) and ipamorelin (for extended cycles or cutting phases). This avoids extended cortisol exposure while still accessing GHRP-6's specific properties when needed.

What to Expect: Timeline

GHRP-6 does not produce rapid or dramatic changes. The mechanism is optimization of endogenous GH pulsatility, which produces gradual improvements in recovery, body composition, and connective tissue quality over weeks, not days.

Sourcing GHRP-6 for Research

Quality control matters for any research peptide. GHRP-6 should be sourced from suppliers providing third-party HPLC purity data and certificates of analysis. Two suppliers with consistent verification standards:

• Pantheon Research -- domestic US fulfillment, HPLC-verified batches, carries GHRP-6 in 5 mg vials.
• Amino Club -- competitive pricing on multi-vial orders, COA available on request.

Frequently Asked Questions